Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/1371
Nucleoside analogues for the treatment of coronavirus infections
Pruijssers, A
Denison, M
Acceso Abierto
Atribución-NoComercial-SinDerivadas
Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV drug development has long been challenged by the activity of a 3' to 5' proofreading exoribonuclease unique to CoVs. Recently, a promising nucleoside analogue with broad-spectrum activity against CoVs has been identified. This review will discuss progress made in the development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections and propose promising strategies for combination therapy.
Current Opinion in Virology
2019
Preimpreso
https://coronavirus.1science.com/item/64b204855f720129bc63e6d7c13752b3324cc5a4
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
108261.pdf398.08 kBAdobe PDFView/Open